Jaime Kulisevsky

List of Publications by Year
in descending order

117	12,380	87723 38	27345 106
papers	citations	h-index	g-index

122	122	122	12425
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intracortical surfaceâ€based MR diffusivity to investigate neurologic and psychiatric disorders: a review. Journal of Neuroimaging, 2022, 32, 28-35.	1.0	7
2	Measuring the functional impact of cognitive impairment in Huntingtonâ€™s disease. Journal of Neurology, 2022, 269, 3541-3549.	1.8	3
3	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.3	13
4	Safinamide in the treatment pathway of Parkinsonâ€™s Disease: a European Delphi Consensus. Npj Parkinson's Disease, 2022, 8, 17.	2.5	7
5	Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntingtonâ€™s Disease. Clinical Neuroradiology, 2022, 32, 1077-1085.	1.0	4
6	MNCD: A New Tool for Classifying Parkinsonâ€™s Disease in Daily Clinical Practice. Diagnostics, 2022, 12, 55.	1.3	3
7	Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1567-1574.	1.5	1
8	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease Patients: A 2-Year Follow-Up Study. Diagnostics, 2022, 12, 1147.	1.3	5
9	A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinson's Disease, 2021, 11, 187-198.	1.5	31
10	Structural brain correlates of irritability and aggression in early manifest Huntingtonâ€™s disease. Brain Imaging and Behavior, 2021, 15, 107-113.	1.1	13
11	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. Journal of Neurology, 2021, 268, 3400-3408.	1.8	12
12	Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease. Parkinsonism and Related Disorders, 2021, 85, 91-94.	1.1	11
13	Robot-induced hallucinations in Parkinsonâ€™s disease depend on altered sensorimotor processing in fronto-temporal network. Science Translational Medicine, 2021, 13, .	5.8	29
14	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	1.1	10
15	Neural signatures of predictive language processing in Parkinson's disease with and without mild cognitive impairment. Cortex, 2021, 141, 112-127.	1.1	4
16	Predictors of Loss of Functional Independence in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	1.3	9
17	Predictors of clinically significant quality of life impairment in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 118.	2.5	17
18	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinsonâ€™s disease. BMC Neurology, 2021, 21, 477.	0.8	7

#	Article	IF	Citations
19	Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinsonâ€™s disease patients and its association with cognitive decline. Brain Imaging and Behavior, 2020, 14, 321-328.	1.1	14
20	Impaired face-like object recognition in premanifest Huntington's disease. Cortex, 2020, 123, 162-172.	1.1	12
21	Preservation of brain metabolism in recently diagnosed Parkinsonâ€™s impulse control disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2165-2174.	3.3	5
22	A collection of three integration-free iPSCs derived from old male and female healthy subjects. Stem Cell Research, 2020, 42, 101663.	0.3	2
23	Structural brain correlates of dementia in Huntingtonâ€™s disease. NeuroImage: Clinical, 2020, 28, 102415.	1.4	19
24	The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates. Frontiers in Neurology, 2020, 11, 240.	1.1	6
25	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	7.0	90
26	Nonâ€motor symptom burden is strongly correlated to motor complications in patients with Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 1210-1223.	1.7	40
27	A Spanish Consensus on the Use of Safinamide for Parkinsonâ€™s Disease in Clinical Practice. Brain Sciences, 2020, 10, 176.	1.1	7
28	Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. Journal of Neurology, 2020, 267, 3400-3410.	1.8	3
29	Author response to Wang et al. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment?. Parkinsonism and Related Disorders, 2020, 77, 159.	1.1	0
30	Utility of the Parkinsonâ€™s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntingtonâ€™s disease. Journal of Neurology, 2020, 267, 1527-1535.	1.8	13
31	Autoscopic phenomena as an atypical psychiatric presentation of Huntington's disease: A case report including longitudinal clinical and neuroimaging data. Cortex, 2020, 125, 299-306.	1.1	1
32	CLU rs11136000 Promotes Early Cognitive Decline in Parkinson's Disease. Movement Disorders, 2020, 35, 508-513.	2.2	15
33	Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2020, 74, 43-49.	1.1	43
34	White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease. NeuroImage: Clinical, 2019, 24, 101965.	1.4	27
35	Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease. NeuroImage: Clinical, 2019, 23, 101900.	1.4	18
36	Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. Parkinsonism and Related Disorders, 2019, 68, 22-25.	1.1	28

#	Article	IF	Citations
37	Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1111-1116.	3.3	15
38	Generation of an integration-free iPSC line, ICCSICi005-A, derived from a Parkinson's disease patient carrying the L444P mutation in the GBA1 gene. Stem Cell Research, 2019, 40, 101578.	0.3	1
39	Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinsonâ€™s disease. Behavioural Brain Research, 2019, 372, 112039.	1.2	6
40	A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene. Stem Cell Research, 2019, 38, 101482.	0.3	3
41	Cognitive and behavioral assessment in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2019, 19, 613-622.	1.4	7
42	Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters. Clinical Nuclear Medicine, 2019, 44, e1-e5.	0.7	11
43	Mild cognitive impairment in Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 897-904.	1.4	33
44	A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. Human Brain Mapping, 2019, 40, 3233-3242.	1.9	38
45	Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease. American Journal of Neuroradiology, 2019, 40, 1464-1468.	1.2	15
46	Differential Expression of Striatal Î”FosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinsonâ€™s Disease. Neurotoxicity Research, 2019, 35, 563-574.	1.3	3
47	Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease. Neurobiology of Disease, 2019, 124, 29-35.	2.1	24
48	An active cognitive lifestyle as a potential neuroprotective factor in Huntington's disease. Neuropsychologia, 2019, 122, 116-124.	0.7	17
49	Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. Movement Disorders, 2019, 34, 78-86.	2.2	58
50	The impact of bilingualism on brain structure and function in Huntington's disease. Parkinsonism and Related Disorders, 2019, 60, 92-97.	1.1	22
51	Historical crossroads in the conceptual delineation of apathy in Parkinsonâ€™s disease. Brain, 2018, 141, 613-619.	3.7	8
52	Long-term Efficacy of Safinamide on Parkinsonâ€™s Disease Chronic Pain. Advances in Therapy, 2018, 35, 515-522.	1.3	47
53	Reduced striatoâ€cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients. Human Brain Mapping, 2018, 39, 54-71.	1.9	7
54	Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Parkinson's Disease, 2018, 2018, 1-5.	0.6	22

#	Article	IF	Citations
55	Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. Frontiers in Psychiatry, 2018, 9, 465.	1.3	24
56	Cortical Thinning Associated with Age and CSF Biomarkers in Early Parkinsonâ€™s Disease Is Modified by the SNCA rs356181 Polymorphism. Neurodegenerative Diseases, 2018, 18, 233-238.	0.8	6
57	Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline. Frontiers in Neurology, 2018, 9, 394.	1.1	12
58	Regional Overlap of Pathologies in Lewy Body Disorders. Journal of Neuropathology and Experimental Neurology, 2017, 76, 216-224.	0.9	45
59	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 216.	4.5	171
60	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	1.1	149
61	Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease. Parkinsonism and Related Disorders, 2017, 44, 95-100.	1.1	33
62	Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). Parkinsonism and Related Disorders, 2017, 43, 73-77.	1.1	8
63	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. ENeurologicalSci, 2017, 8, 44-53.	0.5	10
64	N370Sâ€GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Movement Disorders, 2017, 32, 1409-1422.	2.2	86
65	Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. Movement Disorders, 2017, 32, 165-169.	2.2	19
66	Non-demented Parkinsonâ€™s disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes. Brain Imaging and Behavior, 2017, 11, 1334-1342.	1.1	42
67	Consensus on the Definition of Advanced Parkinsonâ€™s Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson's Disease, 2017, 2017, 1-8.	0.6	53
68	Minor hallucinations occur in drugâ€naive Parkinson's disease patients, even from the premotor phase. Movement Disorders, 2016, 31, 45-52.	2.2	167
69	Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III. Dementia and Geriatric Cognitive Disorders, 2016, 41, 243-250.	0.7	35
70	COPPADIS-2015 (COhort of Patients with PArkinsonâ€™s DIsease in Spain, 2015), a global â€“clinical evaluations, serum biomarkers, genetic studies and neuroimagingâ€“ prospective, multicenter, non-interventional, long-term study on Parkinsonâ€™s disease progression. BMC Neurology, 2016, 16, 26.	0.8	66
71	Striatal hypometabolism in premanifest and manifest Huntingtonâ€™s disease patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2183-2189.	3.3	32
72	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.1	13

#	Article	IF	Citations
73	Parkinson's Diseaseâ€"Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment. Journal of the Neurological Sciences, 2016, 361, 66-71.	0.3	9
74	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Parkinsonism and Related Disorders, 2016, 25, 58-64.	1.1	122
75	Safinamide â€“ A Unique Treatment Targeting Both Dopaminergic and Non-Dopaminergic Systems. European Neurological Review, 2016, 11, 101.	0.5	3
76	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	1.2	32
77	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism and Related Disorders, 2015, 21, 871-876.	1.1	79
78	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the diseaseâ€. Human Molecular Genetics, 2015, 24, 2023-2034.	1.4	45
79	Rasagiline for the treatment of parkinsonism in Huntington's disease. Parkinsonism and Related Disorders, 2015, 21, 340-342.	1.1	0
80	Apathy: who cares?. Lancet Neurology, The, 2015, 14, 465.	4.9	4
81	Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurology, The, 2015, 14, 518-531.	4.9	387
82	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinsonâ€™s Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. Drugs and Aging, 2015, 32, 401-407.	1.3	18
83	Emerging Role of Safinamide in Parkinsonâ€™s Disease Therapy. European Neurological Review, 2015, 9, 108.	0.5	7
84	Mild Cognitive Impairment in Parkinsonâ€™s Disease. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 29-51.	0.3	0
85	Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired Incentive Processing. Journal of Neuroscience, 2014, 34, 5918-5926.	1.7	55
86	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. Clinical Neuropharmacology, 2014, 37, 9-16.	0.2	62
87	The tools of the trade: A state of the art â€œHow to Assess Cognitionâ€•in the patient with Parkinson's disease. Movement Disorders, 2014, 29, 584-596.	2.2	52
88	Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 290-296.	1.1	87
89	Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinsonâ€™s disease experiencing mild wearing-off: a randomised, double-blind trial. Journal of Neural Transmission, 2014, 121, 357-366.	1.4	23
90	Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. Journal of Parkinson's Disease, 2014, 4, 585-589.	1.5	15

#	Article	IF	Citations
91	Parkinson's Disease: From Genetics to Clinical Practice. Current Genomics, 2014, 14, 560-567.	0.7	19
92	Parkinson's diseaseâ€cognitive rating scale: Psychometrics for mild cognitive impairment. Movement Disorders, 2013, 28, 1376-1383.	2.2	58
93	Selecting deep brain stimulation or infusion therapies in advanced Parkinsonâ€™s disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	1.8	128
94	Predicting dementia development in Parkinson's disease using Bayesian network classifiers. Psychiatry Research - Neuroimaging, 2013, 213, 92-98.	0.9	64
95	Measuring functional impact of cognitive impairment: Validation of the Parkinson's Disease Cognitive Functional Rating Scale. Parkinsonism and Related Disorders, 2013, 19, 812-817.	1.1	69
96	Apathy in Parkinson's Disease: More Than Just Executive Dysfunction. Journal of the International Neuropsychological Society, 2013, 19, 571-582.	1.2	43
97	New Subtype of Spinocerebellar Ataxia With Altered Vertical Eye Movements Mapping to Chromosome 1p32. JAMA Neurology, 2013, 70, 764.	4.5	36
98	Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e54980.	1.1	112
99	Advances with MRI in Parkinson disease. Neurology, 2012, 79, 2222-2223.	1.5	1
100	Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinsonâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2012, 34, 312-318.	0.7	24
101	Adenosine A_{2A}-Receptor Antagonism and Pathophysiology of Parkinsonâ€™s Disease and Drug-Induced Movement Disorders. European Neurology, 2012, 67, 4-11.	0.6	31
102	Efficacy of trazodone in antipsychotic-induced akathisia resistant to conventional treatment. Parkinsonism and Related Disorders, 2012, 18, 902-903.	1.1	9
103	Cognitive impairment and dementia in Parkinson's disease. Neurobiology of Disease, 2012, 46, 590-596.	2.1	198
104	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disorders, 2012, 27, 393-399.	2.2	144
105	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders, 2012, 27, 349-356.	2.2	1,908
106	Is all cognitive impairment in Parkinsonâ€™s disease â€œmild cognitive impairmentâ€?. Journal of Neural Transmission, 2011, 118, 1185-1190.	1.4	32
107	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PDâ€MCI. Movement Disorders, 2011, 26, 1814-1824.	2.2	649
108	Cognitive impairment in nondemented Parkinson's disease. Movement Disorders, 2011, 26, 2483-2495.	2.2	115

#	Article	IF	Citations
109	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.9	125
110	Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment. Movement Disorders, 2009, 24, 1103-1110.	2.2	159
111	Parkinson's diseaseâ€cognitive rating scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders, 2008, 23, 998-1005.	2.2	264
112	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	2.2	4,796
113	Levodopa and executive performance in Parkinson's disease: A randomized study. Journal of the International Neuropsychological Society, 2008, 14, 832-841.	1.2	41
114	Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. Movement Disorders, 2007, 22, 62-67.	2.2	67
115	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients. Movement Disorders, 2000, 15, 613-626.	2.2	148
116	Role of Dopamine in Learning and Memory. Drugs and Aging, 2000, 16, 365-379.	1.3	152
117	Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain, 1996, 119, 2121-2132.	3.7	142